Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.

Molecular cancer therapeutics - 1 Jun 2003

Shi Yijiang, Gera Joseph, Hsu Jung-Hsin, Van Ness Brian, Lichtenstein Alan

Abstract excerpt

Farnesyl transferase inhibitors (FTIs) are anticancer agents designed to target ras processing and ras-dependent signal pathways. Because oncogenic ras mutations are found in up to 50% of multiple myeloma (MM) specimens, these agents may be effective in this disease. However, some preclinical stu...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkyl and Aryl Transferases
Share to Farnesyltranstransferase
Share to Mitogen-Activated Protein Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multiple Myeloma

Share to NF-kappa B

Share to Ribosomal Protein S6 Kinases, 70-kDa

Share to Tetrazolium Salts

Share to Thiazoles

Source

Identifiers

PMID: 12813136

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-12813136-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.PMID 12813136Read ↗

Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells.Semantic proximity Read ↗

Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro.Semantic proximity Read ↗

The effect of azacitidine on interleukin-6 signaling and nuclear factor- B activation and its in vitro and in vivo activity against multiple myelomaSemantic proximity Read ↗

Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells.Semantic proximity Read ↗

Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6.Semantic proximity Read ↗

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival.Semantic proximity Read ↗

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myelomaSemantic proximity Read ↗

Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis.Semantic proximity Read ↗

Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses.Semantic proximity Read ↗

Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation.Semantic proximity Read ↗

Study on the growth inhibition of human multiple myeloma cells by an IL-6Ralpha mutant.Semantic proximity Read ↗

Mcl‐1 and Bcl‐x<sub>L </sub> are co‐regulated by IL‐6 in human myeloma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.